EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.
EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.
2018 Korea CPHI, C30
EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.
1.
Pimavanserin tartrate, CAS#706779-91-1, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than56KG in stock, pls check:
Name: Pimavanserin tartrate
CAS#: 706779-91-1
Formula: C25H34FN3O2
Exact Mass: 427.26351
Molecular Weight: 427.56
Elemental Analysis: C, 70.23; H, 8.02; F, 4.44; N, 9.83; O, 7.48
Exact Mass: 427.26351
Molecular Weight: 427.56
Elemental Analysis: C, 70.23; H, 8.02; F, 4.44; N, 9.83; O, 7.48
Appearance: white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
2.
Pimavanserin tartrate Intermediates:
1. Pimavanserin tartrate Intermediate:4-(4-fluorobenzylamino)-1-methylpiperidine
1. Pimavanserin tartrate Intermediate:4-(4-fluorobenzylamino)-1-methylpiperidine
Cas#359878-47-0
We have more than67kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
2. Pimavanserin tartrate Intermediate:p-Isobutyloxybenzylamin acetate
Cas#955997-89-4
We have more than 58kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Reference：
1: Chendo I, Ferreira JJ. Pimavanserin for the treatment of Parkinson's disease psychosis. Expert Opin Pharmacother. 2016 Oct;17(15):2115-24. doi: 10.1080/14656566.2016.1234609. Epub 2016 Sep 15. PubMed PMID: 27609312.
2: Hussar DA, Dimaculangan CA. Reslizumab, ixekizumab, and pimavanserin tartrate. J Am Pharm Assoc (2003). 2016 Sep-Oct;56(5):595-8. doi: 10.1016/j.japh.2016.08.002. PubMed PMID: 27594111.
3: Stahl SM. Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors. CNS Spectr. 2016 Aug;21(4):271-5. doi: 10.1017/S1092852916000407. PubMed PMID: 27503570.
4: Markham A. Pimavanserin: First Global Approval. Drugs. 2016 Jul;76(10):1053-7. doi: 10.1007/s40265-016-0597-9. PubMed PMID: 27262680.
5: Traynor K. Pimavanserin approved for Parkinson's-related hallucinations, delusions. Am J Health Syst Pharm. 2016 Jun 15;73(12):853. doi: 10.2146/news160037. PubMed PMID: 27261226.
6: Pimavanserin (Nuplazid) for Parkinson's disease psychosis. Med Lett Drugs Ther. 2016 Jun 6;58(1496):74-5. PubMed PMID: 27249096.
7: Howland RH. Pimavanserin: An Inverse Agonist Antipsychotic Drug. J Psychosoc Nurs Ment Health Serv. 2016 Jun 1;54(6):21-4. doi: 10.3928/02793695-20160523-01. PubMed PMID: 27245248.
8: Banks ML. Effects of 7-day repeated treatment with the 5-HT2A inverse agonist/antagonist pimavanserin on methamphetamine vs. food choice in male rhesus monkeys. Drug Alcohol Depend. 2016 Aug 1;165:260-4. doi: 10.1016/j.drugalcdep.2016.05.014. Epub 2016 May 27. PubMed PMID: 27242287; PubMed Central PMCID: PMC4939103.
9: Hermanowicz S, Hermanowicz N. The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease. Expert Rev Neurother. 2016 Jun;16(6):625-33. doi: 10.1586/14737175.2016.1158102. PubMed PMID: 26908168.
10: Hunter NS, Anderson KC, Cox A. Pimavanserin. Drugs Today (Barc). 2015 Nov;51(11):645-52. doi: 10.1358/dot.2015.51.11.2404001. Review. PubMed PMID: 26744739.
11: Andersen VL, Hansen HD, Herth MM, Dyssegaard A, Knudsen GM, Kristensen JL. (11)C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand. Bioorg Med Chem Lett. 2015 Mar 1;25(5):1053-6. doi: 10.1016/j.bmcl.2015.01.017. Epub 2015 Jan 20. PubMed PMID: 25655720.
12: Hacksell U, Burstein ES, McFarland K, Mills RG, Williams H. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis. Neurochem Res. 2014 Oct;39(10):2008-17. doi: 10.1007/s11064-014-1293-3. Epub 2014 Mar 30. Review. PubMed PMID: 24682754; PubMed Central PMCID: PMC4172996.
13: Meltzer HY, Roth BL. Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. J Clin Invest. 2013 Dec;123(12):4986-91. doi: 10.1172/JCI70678. Epub 2013 Dec 2. Review. PubMed PMID: 24292660; PubMed Central PMCID: PMC3859385.
14: Kingwell K. Parkinson disease: Pimavanserin could be useful for treating psychosis in Parkinson disease. Nat Rev Neurol. 2013 Dec;9(12):658. doi: 10.1038/nrneurol.2013.233. Epub 2013 Nov 19. PubMed PMID: 24247322.
15: Fox SH. Pimavanserin as treatment for Parkinson's disease psychosis. Lancet. 2014 Feb 8;383(9916):494-6. doi: 10.1016/S0140-6736(13)62157-1. Epub 2013 Nov 1. PubMed PMID: 24183566.
16: Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014 Feb 8;383(9916):533-40. doi: 10.1016/S0140-6736(13)62106-6. Epub 2013 Nov 1. Erratum in: Lancet. 2014 Jul 5;384(9937):28. PubMed PMID: 24183563.
17: Friedman JH. Pimavanserin for the treatment of Parkinson's disease psychosis. Expert Opin Pharmacother. 2013 Oct;14(14):1969-75. doi: 10.1517/14656566.2013.819345. Review. PubMed PMID: 24016069.
18: Hubbard D, Hacksell U, McFarland K. Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios. Behav Pharmacol. 2013 Oct;24(7):628-32. doi: 10.1097/FBP.0b013e3283656db6. PubMed PMID: 23969614.
19: Meltzer HY, Elkis H, Vanover K, Weiner DM, van Kammen DP, Peters P, Hacksell U. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophr Res. 2012 Nov;141(2-3):144-52. doi: 10.1016/j.schres.2012.07.029. Epub 2012 Sep 4. PubMed PMID: 22954754.
20: Price DL, Bonhaus DW, McFarland K. Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease. Behav Pharmacol. 2012 Aug;23(4):426-33. doi: 10.1097/FBP.0b013e3283566082. PubMed PMID: 22750845.
